Browsing by Author "Moore, Kathleen N"
Now showing items 1-4 of 4
-
First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion
Gonzalez-Martin, Antonio; Harter, Philipp; Lorusso, Domenica; Moore, Kathleen N; Oaknin Benzaquen, Ana Mazaltob; Banerjee, Susana (BMJ, 2020-12-11) -
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
Moore, Kathleen N; Oza, Amit M.; Oaknin Benzaquen, Ana Mazaltob; Lorusso, Domenica; Scambia, Giovanni; Colombo, Nicoletta (Elsevier, 2021-06) -
Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study
Santin, Alessandro; González-Martin, Antonio; Moore, Kathleen N; Oaknin Benzaquen, Ana Mazaltob; Romero, Ignacio; Vergote, Ignace (BMJ, 2023-04) -
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial
Moore, Kathleen N; Oaknin Benzaquen, Ana Mazaltob; Friedlander, Michael; Lisyanskaya, Alla; Scambia, Giovanni; Colombo, Nicoletta (Elsevier, 2021-10)